Darbepoetin alfa (Aranesp™) in children with chronic renal failure

Kidney International

Volumn 68, Issue 4, 2005, Pages 1759-1765

  Geary, Dems F ^a   Keating, Laura E ^a   Vigneux, Annette ^a   Stephens, Derek ^a   Hébert, Diane ^a   Harvey, Elizabeth A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Anemia; Chronic renal failure; Darbepoetin alfa; Dialysis; Pediatrics

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADOLESCENT; ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; INFORMED CONSENT; INJECTION SITE PAIN; KIDNEY FAILURE; MALE; OUTCOME ASSESSMENT; PATIENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADOLESCENT; ANEMIA; ANTIBODIES; CHILD; CHILD, PRESCHOOL; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; INFANT; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 31644439003     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00592.x     Document Type: Article

References (15)

1. JABS K, HARMON W: Recombinant human erythropoietin therapy in children on dialysis. Adv Ren Replace Ther 3:24-36, 1996
2. VAN DAMME-LOMBAERTS R, HERMAN J: Erythropoietin treatment in children with renal failure. Pediatr Nephrol 13:148-152, 1999
3. ESCHBACH JW, ABDULHADI MH, BROWNE JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
4. MACDOUGALL IC: Novel erythropoiesis stimulating protein. Semin Nephrol 20:375-381, 2000
5. LERNER G, KALE AS, WARADY BA, et al: Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 17:933-937, 2002
6. EVANS JH, BROCKLEBANK JT, BOWMER CJ, NG PC: Pharmokinetics of recombinant human erythropoietin in children with renal failure. Nephrol Dial Transplant 6:709-714, 1991
7. DE PALO T, GIORDANO M, PALUMBO F, et al: Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 19:337-340, 2004
8. SCHWARTZ GJ, BRION LP, SPITZER A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin N Am 34:571-590, 1987
9. THERAPEUTIC PRODUCTS DIRECTORATE: Good Clinical Practice: Consolidated Guideline, Ottawa, Ontario, Minister of Public Works and Government Services Canada, 1997
10. SURANYI MG, LINDBERG JS, NAVARRO J, et al: Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 23:106-111, 2002
11. VANRENTERGHEM Y, BÁRÁNY P, MANN JFE, et al: Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62:2167-2175, 2002
12. JADOUL M, VANRENTERGHEM Y, FORET M, et al: Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19:898-903, 2004
13. CASTELLI G, FAMULARO A, SEMINO C, et al: Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol Res 41:313-318, 2000
14. CASADEVALL N, NATAF J, VIRON B, et al: Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
15. JANSSEN-ORTHO: Important Drug Safety Update: Eprex(r) (epoetin alfa): Pure Red Cell Aplasia, Toronto, Janssen-Ortho, Inc., Ortho Biotech, 2002